Pain and Regional Anesthesia
Nerve Injury Induces a Tonic Bilateral μ-Opioid Receptor–mediated Inhibitory Effect on Mechanical Allodynia in Mice
Mansikka, Heikki M.D., Ph.D.*; Zhao, Chengshui Ph.D.†; Sheth, Rishi N. M.D.‡; Sora, Ichiro M.D., Ph.D.§; Uhl, George M.D., Ph.D.∥; Raja, Srinivasa N. M.D.#
Background: Mice lacking the μ-opioid receptor gene have been used to characterize the role of μ-opioid receptors in nociception and the analgesic actions of opioid agonists. In this study, the authors determined the role of μ-opioid receptors in neuropathic pain behaviors and the effectiveness of μ- and κ-opioid receptor agonists on this behavior in mice.
: The authors studied the behavioral responses of μ-opioid receptor knockout and wild-type mice to thermal and mechanical stimuli before and after neuropathic pain induced by unilateral ligation and section of the L5 spinal nerve. Response to mechanical stimuli was evaluated by determining the frequency of hind paw withdrawal to repetitive stimulation using a series of von Frey monofilaments. Thermal hyperalgesia was assessed by determining the paw withdrawal latencies to radiant heat and frequency of hind paw withdrawal to cooling stimuli. The effects of systemic morphine, the κ-opioid agonist U50488H, and naloxone on responses to mechanical and thermal stimuli were also studied in spinal nerve–injured mice.
: After spinal nerve injury, wild-type mice developed increased responsiveness to mechanical, heat, and cooling stimuli ipsilateral to nerve injury. μ-Opioid receptor knockout mice not only had more prominent mechanical allodynia in the nerve-injured paw, but also expressed contralateral allodynia to mechanical stimuli. Hyperalgesia to thermal stimuli was similar between μ-opioid knockout and wild-type animals. Morphine decreased mechanical allodynia dose dependently (3–30 mg/kg subcutaneous) in wild-type mice—an effect that was attenuated in the heterozygous mice and absent in the homozygous μ-opioid knockout mice. The κ-opioid agonist U50488H (3–10 mg/kg subcutaneous) attenuated mechanical allodynia in wild-type, heterozygous, and homozygous μ-opioid mice. Naloxone in wild-type mice resulted in enhanced ipsilateral and contralateral allodynia to mechanical stimuli that resembled the pain behavior observed in μ-opioid receptor knockout mice.
Conclusions: The authors’ observations indicate that (1) unilateral nerve injury induces a bilateral tonic activation of endogenous μ-opioid receptor–mediated inhibition that attenuates mechanical allodynia but not thermal hyperalgesia, (2) both μ- and κ-opioid agonists attenuate neuropathic pain in mice, and (3) the antihyperalgesic actions of morphine are mediated primarily via μ-opioid receptors.
NEUROPATHIC pain has been reported to respond poorly to treatment with opioids, a phenomenon that is in contrast to the enhanced effect of opioid agonists in inflammatory pain. 1–3
Recent clinical studies, however, indicate that neuropathic pain is not resistant to opioids, and patients with peripheral and central neuropathic pain may benefit from therapy with oral opioids. 4–6
Animal studies have reported both increased and decreased effects of opioids on neuropathic pain. 7–11
These discrepancies in pharmacologic studies may in part be due to lack of in vivo
selectivity of various opioid compounds. Hence, it is difficult to exclude that the analgesic effects of opioids considered to be highly selective for a given receptor are not confounded by their actions on other receptor subtypes in vivo
Recently, mice lacking μ-, δ-, or κ-opioid receptors have been produced by homologous recombination. Studies in these animals have provided new insights on the roles of the different opioid receptors. The analgesic effects of morphine have been shown to be mediated primarily by μ-opioid receptors as determined on various acute thermal and mechanical nociceptive tests. 13–15
κ-Opioid receptor–mediated analgesia is reported to be unaffected in μ-opioid receptor knockout mice. 15,16
In contrast, δ-opioid receptor agonist–mediated analgesia has been shown to be reduced in μ-opioid receptor knockout mice, indicating an interaction between μ- and δ-opioid receptors. 15–17
Phenotypic changes in dorsal root ganglia and spinal and supraspinal neurons have been observed after inflammation and peripheral nerve injury. 18,19
After inflammation and polyarthritis, an increase in density of spinal opiate receptors, synthesis of opioid peptides, and functional activity of opiate receptors have been reported. 20–22
Persistent inflammation results in increased endogenous opioid tone and enhanced antihyperalgesic and antinociceptive effects of exogenous opioid agonists. 23,24
It is unclear whether similar alterations in opioid receptor activity plays a role in the mechanisms of neuropathic pain resulting from nerve injury.
Spinal nerve injury in rats results in a neuropathic pain–like behavior characterized by hyperalgesia to mechanical and thermal stimuli. 25,26
This animal model has been used to study the underlying mechanisms of neuropathic pain and to help develop rational therapies for clinical neuropathic pain. To better understand the role of μ-opioid receptors in neuropathic pain, we compared the neuropathic pain behavior that develops after spinal nerve injury in μ-opioid receptor knockout and wild-type control mice. Complementary pharmacologic studies with systemic administration of naloxone were conducted in wild-type mice to determine whether nerve injury results in opioid receptor–mediated tonic inhibitory activity. In addition, to assess the effectiveness of opioid receptor agonists on neuropathic pain, we studied the effects of morphine and the κ-opioid agonist, U50488H, on neuropathic pain behavior.
Materials and Methods
The experiments were performed using μ-opioid receptor knockout homozygous (n = 19), heterozygous (n = 17), and wild-type (n = 27) mice. Mice deficient in μ-opioid receptor were generated by gene targeting as described earlier. 14
The animals were maintained in a 12-h light–dark cycle and were provided with food and water ad libitum
. The μ-opioid receptor knockout animals were grossly normal developmentally, were fertile, and seemed healthy. Knockout animals could not be separated from the wild-type mice by their appearance. Animals were allowed to habituate for 5 days to the testing environment and for 15 min each day before the behavioral studies were started. The studies were performed with the investigators blinded to the genotype of the mice. The research protocol was approved by the Johns Hopkins Animal Care and Use Committee (Baltimore, Maryland).
The animals underwent surgery under halothane anesthesia. The skin on the back was shaved and cleaned with a 10% povidone–iodine solution. After a dorsolateral skin incision on the back, the muscle layer was incised. After the transverse process of L6 was identified, it was freed of its muscular attachments and removed with forceps. The exposed L5 spinal nerve was isolated, ligated with a 6-0 silk suture, and transected just distal to the knot. After confirming hemostasis, the muscle layer was closed with a 6-0 silk suture, and the skin was stapled. Throughout surgery, the animals were kept warm with use of a heating pad. The animals were returned to their cages to recover.
Withdrawal Frequencies to Mechanical Stimuli
Mechanical withdrawal frequencies were measured by calibrated von Frey monofilaments (Stoelting Co., Wood Dale, IL). Mice were placed in a clear plastic chamber on an elevated mesh screen. The von Frey monofilaments were applied to the plantar surface of each hind paw in ascending series. The monofilaments used in this study produced forces of 0.06, 0.20, 0.52, 1.15, 2.86, and 4.43 g. Every monofilament was applied to the hind paw for approximately 1 s. Each hind paw was studied with ascending series of monofilaments five times. A positive withdrawal response was defined as a mechanical stimulus–related withdrawal of the tested paw. The frequency of paw withdrawal (percent) was calculated for each monofilament.
Behavioral Responses to Thermal Stimuli
To measure withdrawal latency to radiant heat, mice were placed on a glass plate preheated to a constant temperature of 30°C, surrounded by a Plexiglas chamber (model 336 Analgesia Meter; IITC Inc./Life Science Instruments, Woodland Hills, CA). Radiant heat was applied from below to the plantar surface of each hind paw, and the withdrawal latency was measured by an electronic timer. 27
Three measurements were performed in each hind paw, spaced at least 1 min apart to determine mean withdrawal latency. A cutoff time of 20 s was used for the heat stimulus to avoid damage to cutaneous tissues.
To measure withdrawal frequencies to cold stimuli, mice were placed in a Plexiglas chamber on an elevated mesh screen. A small bubble of acetone was formed at the tip of polyethylene tubing connected to a syringe, which was applied to the plantar surface of the foot. 26
The acetone bubble was applied to each hind paw five times, with at least 2-min intervals between applications. Brisk foot withdrawal and licking of the treated paw were considered positive responses. The frequency of paw withdrawal (percent) was calculated for both paws.
Baseline behavioral responses to heat, cold, and mechanical stimuli were measured 1 day before surgery. After the L5 spinal nerve section, behavioral responses were determined on days 1, 7, 14, and 28 after surgery.
Effects of Systemic Naloxone on Neuropathic Pain Behavior of Wild-type Mice
To examine the effects of endogenous opiate systems on nerve injury–induced mechanical and thermal hyperalgesia, the effects of naloxone (0.1 and 1.0 mg/kg subcutaneous, n = 8) and saline were tested in wild-type and μ-opioid knockout mice. The selection of the dose of naloxone was based on our previous studies indicating that the higher dose was adequate to block the effects of both μ- and κ- opioid agonists. 15
Paw withdrawal frequencies to the 0.52-g von Frey hair were tested before and 5 or 6 days after spinal nerve injury and normal saline or naloxone were administered. Similar studies were conducted using radiant heat stimuli to examine the effects of naloxone on heat hyperalgesia in wild type mice.
Effects of Systemic Morphine or U50488H on Neuropathic Pain Behavior
The effect of morphine (on postoperative day 20) or the κ-opioid receptor agonist, U50488H (on postoperative day 23), on mechanical withdrawal frequencies after spinal nerve injury was tested in wild-type, heterozygous, and homozygous μ-opioid receptor knockout mice (n = 7–9/group). The effects of morphine on the response to cooling and heat stimuli were also examined in a separate group of animals 8 and 13 days after nerve injury, respectively (n = 8–10/group). To test the effects of morphine and U50488H, a cumulative drug-dosing regimen was used (saline, 3, 10, 30 mg/kg morphine or saline, 3, 10 mg/kg U50488H). The interval between drug injections was 40 min. The drugs were administered subcutaneously, and at the end of the cumulative dose regimen, animals received a subcutaneous injection of naloxone (1 mg/kg). Responses to mechanical and heat stimuli were tested 20 min after each injection of a drug dose and immediately before administration of the next drug dose.
Data on frequency of paw withdrawals to mechanical and cold stimuli were analyzed using nonparametric tests, Friedman two-way analysis of variance by ranks, and Kruskal Wallis tests followed by Wilcoxon matched-pairs and Mann–Whitney U tests. Radiant heat–evoked latencies were analyzed with repeated-measures analysis of variance followed by the Tukey test. All statistical analyses were performed using the statistical software package Statistica (StatSoft, Inc., Tulsa, OK). P < 0.05 was considered significant. Data are presented as mean ± SD unless otherwise indicated.
Altered Responses to Mechanical Stimuli after Nerve Injury
Before nerve injury, withdrawal frequencies to von Frey hairs (range, 0.06–4.43 g) were similar in both hind paws and were not significantly different in the three genotypes, homozygous and heterozygous μ-opioid receptor mutant mice and wild-type mice (P
> 0.05, Mann–Whitney U test;figs 1 and 2
; data for heterozygous not shown). After the L5 spinal nerve injury, withdrawal frequencies increased ipsilateral to nerve injury starting from day 1 in all groups compared with presurgery values and with the contralateral side (P
< 0.05, Wilcoxon matched-pairs test or Mann–Whitney U test;figs. 1 and 2
). Increased responsiveness to mechanical stimulation lasted until the end of the 4-week observation period.
In the homozygous μ-opioid receptor knockout group, mechanical withdrawal frequencies ipsilateral to injury were significantly greater than in the wild-type ipsilateral hind paw at all time points studied (postoperative days 1, 7, 14, and 28; P
< 0.05, Mann–Whitney U test;fig. 2
). Also, in the homozygous μ-opioid receptor knockout mice, withdrawal frequencies in the contralateral
paw increased significantly from baseline values (P
< 0.05, Wilcoxon matched-pairs test;figs. 1 and 2
). Of note, in homozygous mice, allodynia to mechanical stimuli contralateral to nerve injury was as severe as allodynia in the ipsilateral paw of wild-type mice (P
> 0.05, Mann–Whitney U test;figs. 1 and 2
). In the wild-type mice, an increase in withdrawal frequency to mechanical stimuli of the contralateral hind paw was observed only with the higher von Frey forces on day 7 (fig. 1
). The mechanical hyperalgesia in heterozygous μ-opioid mutant mice was intermediate between the μ-opioid knockout and wild-type mice but was restricted to the paw ipsilateral to the nerve injury (data not shown).
Altered Responses to Radiant Heat after Nerve Injury
Latencies to radiant heat were not significantly different between different genotypes or ipsilateral versus
contralateral paws before nerve injury (P
> 0.05, analysis of variance;fig. 3
). Response latencies to radiant heat decreased significantly in the ipsilateral but not contralateral paw after nerve injury in all three groups of mice (P
< 0.05, analysis of variance;fig. 3
). In contrast to mechanical hyperalgesia, hyperalgesia to heat stimuli returned to baseline on day 28. The reductions in withdrawal latencies in the paw ipsilateral to nerve injury were similar in the three genotypes of mice at all time points (days 1, 7, 14 and 28; P
> 0.05, Tukey test;fig. 3
Altered Responses to Cooling Stimuli after Nerve Injury
Before the nerve injury, withdrawal frequencies to acetone application were not significantly different between the different genotypes and between the ipsilateral and contralateral paws (P
> 0.05, Mann–Whitney U test;fig. 4
). Response frequencies to acetone application increased ipsilateral to nerve injury starting from day 1 in all three groups of mice compared with presurgery values and with the contralateral side (P
< 0.05, Wilcoxon matched-pairs test or Mann–Whitney U test;fig. 4
). Increased responses were measured in all groups until the end of the 4-week testing period. Cold allodynia was similar in homozygous, heterozygous, and wild-type mice.
Effects of Naloxone on Nerve Injury–induced Neuropathic Pain Behavior
Systemic administration of naloxone (0.1 and 1 mg/kg), 5 days after spinal nerve section, increased the mechanical withdrawal frequencies in the paw ipsilateral to the nerve injury in wild-type mice (fig. 5A
) but not in μ-opioid receptor knockout mice. Allodynia to mechanical stimuli was also observed in the contralateral paw of wild-type mice. The bilateral allodynia to mechanical stimuli in the wild-type mice after the high dose of naloxone resembled the pain behavior observed in the μ-opioid knockout mice. Systemic administration of naloxone, 6 or 7 days after spinal nerve section, had no significant effects on the paw withdrawal latencies to radiant heat in wild-type mice ipsilateral to the nerve injury (fig. 5B
). The lack of an effect of naloxone on response to heat stimuli is consistent with a lack of observed difference in wild-type and μ-opioid knockout mice in heat hyperalgesia.
Effects of Morphine on Mechanical Withdrawal Frequencies
Systemic administration of morphine (3–30 mg/kg subcutaneous) or naloxone (1 mg/kg subcutaneous) did not have significant effects on the mechanical withdrawal frequencies in homozygous μ-opioid knockout mice (fig. 6
). In the heterozygous μ-opioid knockout mice, morphine significantly attenuated the mechanical withdrawal frequencies only at a dose of 30 mg/kg (fig. 6
). The response frequencies ipsilateral to nerve injury were still significantly higher compared with the contralateral side after 30 mg/kg morphine, indicating that morphine did not completely reverse mechanical allodynia in the heterozygous mice. In the wild-type mice, morphine was effective in attenuating mechanical withdrawal frequencies dose dependently, starting from the lowest dose of 3 mg/kg subcutaneous (fig. 6
). Attenuation of mechanical withdrawal responses were seen bilaterally after morphine administration. With the highest dose of morphine (30 mg/kg subcutaneous), the responses ipsilateral to nerve injury were not significantly different from the contralateral side, indicating that this dose was able to abolish mechanical allodynia. Attenuation of mechanical withdrawal responses after morphine administration in heterozygous and wild-type mice were naloxone reversible (fig. 6
Effects of Morphine on Paw Withdrawal Latencies to Radiant Heat
Systemic administration of morphine (3 and 10 mg/kg subcutaneous) or naloxone (1 mg/kg) did not have significant effects on the paw withdrawal latencies to radiant heat in homozygous and heterozygous μ-opioid knockout mice (fig. 7A
). The effects of the 30-mg/kg dose of morphine on paw withdrawal latencies to heat stimuli could not be tested because this dose resulted in increased locomotor activity. In contrast to transient (approximately 1 s) stimulus durations with von Frey hairs and acetone, successful measurement of paw withdrawal latencies to heat required a stimulus duration of approximately 10 s. In the wild-type mice, morphine (10 mg/kg) attenuated the paw withdrawal latencies to radiant heat ipsilateral to the nerve injury (fig. 7A
< 0.05) but had no significant effect on the contralateral paw response. The effects of morphine were reversed by naloxone (1 mg/kg subcutaneous).
Effects of Morphine on Paw Withdrawal Frequencies to Acetone
Systemic administration of morphine (3–30 mg/kg subcutaneous) or naloxone (1 mg/kg) did not have significant effects on the paw withdrawal frequencies to acetone in homozygous μ-opioid receptor knockout mice (fig. 7B
). In the heterozygous μ-opioid receptor knockout mice and wild-type mice, morphine dose-dependently attenuated the paw withdrawal frequencies ipsilateral to nerve injury, but the effect of morphine in heterozygous μ-opioid knockout mice was less than that in wild-type mice. The effects of morphine in the heterozygous μ-opioid receptor knockout mice and wild-type mice were reversed by naloxone (1 mg/kg subcutaneous).
Effects of U50488H on Mechanical Withdrawal Frequencies
Systemic administration of U50488H had significant effects on mechanical withdrawal frequencies in homozygous, heterozygous, and wild-type mice. In the homozygous mice, U50488H decreased the mechanical withdrawal frequencies in both paws (fig. 8
). After U50488H administration, a significant difference persisted between ipsilateral and contralateral paw mechanical withdrawal responses in the homozygous mice. In the heterozygous and wild-type mice, administration of U50488H also attenuated mechanical withdrawal responses bilaterally and dose dependently (fig. 8
). After 10 mg/kg subcutaneous U50488H in the wild-type and in the heterozygous mice, there was no significant difference in mechanical withdrawal responses between the nerve-injured and the contralateral side. The effects of U50488H could be reversed by naloxone (1 mg/kg subcutaneous;fig. 8
The primary observations in the current study are that (1) L5 spinal nerve injury–induced mechanical allodynia is enhanced bilaterally, i.e., ipsilateral and contralateral paw, in μ-opioid receptor knockout mice; (2) L5 spinal nerve injury–induced hyperalgesia to heat and cooling stimuli is not affected by the absence of μ-opioid receptors; (3) systemic naloxone administration in wild-type mice after spinal nerve injury results in enhanced bilateral mechanical allodynia that mimics the neuropathic pain behavior observed in μ-opioid receptor knockout mice; (4) systemic morphine attenuates the nerve injury–induced increased responses to mechanical, heat, and cooling stimuli in control mice primarily by a μ-opioid receptor–mediated effect; and (5) systemic administration of a κ-opioid receptor agonist reduces neuropathic pain behavior, an effect that is independent of the μ-opioid receptor.
Studies in transgenic mice have been used in recent years to understand the role of different receptor mechanisms in the signaling of pain. However, it has been suggested that the use of gene knockout mice for studies of pain must be interpreted with caution because of the potential for confounding, compensatory factors. 28
Knocking out a gene might lead to compensatory changes in the expression of other genes or nonspecific changes affecting the behavior of the animal. The μ-opioid receptor knockout mice are a random mix of 129/sv and C57BL/6 alleles, which might also be a confounding factor because different strains have different sensitivities to noxious stimuli. 29
However, in the current study, mechanical and thermal withdrawal responses were similar before the nerve injury in wild-type and μ-opioid receptor knockout mice, which suggests that the general behavior and sensitivity to acute noxious stimuli were not affected by the deletion of the μ-opioid receptor gene. Moreover, autoradiographic studies failed to show major quantitative differences in κ- or δ-opioid receptor binding in the brain of μ-opioid receptor mutant mice. 30
Finally, the observed effects in μ-opioid receptor knockout mice were mimicked by the opioid receptor antagonist naloxone in wild-type animals.
Our observations of an enhanced mechanical allodynia in the absence of μ-opioid receptors provide evidence to suggest that nerve injury induces the development of a tonic opioid receptor–mediated inhibitory mechanism—a potential compensatory neuronal response to attenuate the pain signals. The withdrawal frequencies to mechanical stimuli were similar in homozygous, heterozygous, and wild-type mice before the nerve injury. This finding is similar to our previous observations 15
that mechanical withdrawal responses are not different between μ-opioid receptor knockout and wild-type mice under normal conditions. Earlier reports with the use of opioid receptor antagonists in normal human subjects also indicated that tonic endogenous opioid receptor–mediated modulatory effects on nociception are minimal in the absence of tissue injury. 31,32
However, we observed that the mechanical allodynia resulting from spinal nerve injury was enhanced in the μ-opioid receptor knockout mice, and in wild-type mice after naloxone administration. These observations suggest that tonic μ-opioid receptor–mediated control mechanisms are induced by the nerve injury. A similar activation of the endogenous opioid system has been reported after peripheral inflammation and spinal cord injury. 23,24,33
In addition, dental postoperative pain has been reported to be enhanced after naloxone administration. 34
However, naloxone does not affect pain thresholds in normal subjects or in normal rats, indicating that activating the endogenous opiate system requires a long-lasting noxious stimulus. 31,34,35
This endogenous μ-opioid receptor–mediated inhibition of neuropathic pain is not restricted to the side of nerve injury because knockout mice expressed also a robust contralateral mechanical allodynia. Our observations are consistent with previous studies showing a bilateral increase in μ-opioid receptor binding in spinal dorsal horn after a unilateral chronic constriction injury of the sciatic nerve. 36
Unilateral nerve injury in rats has also been shown to induce mechanical hyperalgesia in the contralateral side. 25,26,37
Contralateral changes are usually less marked and have a shorter time course than ipsilateral changes. Other chronic pain states, such as persistent inflammation, also alter the pharmacology and physiology of supraspinal neurons and lead to an increased potency of opioid agonist in suppressing nociceptive responses of the contralateral, uninflamed paw. 38
Our results indicate that contralateral pain behavior after nerve injury is under control of endogenous opiate mechanisms because contralateral allodynia to mechanical stimuli was evident in the control mice only after the administration of naloxone. This contralateral hyperalgesia seems also to be modality specific because contralateral changes were observed only with mechanical, not thermal, stimuli.
The site of modulatory actions of the μ-opioid system in neuropathic pain must be defined by additional studies. The bilateral effects of endogenous opioid mechanisms on mechanical allodynia suggest a central site of action. A recent report indicates that, compared with control animals, the efficacy of intrathecal morphine in attenuating pain behavior was decreased after spinal nerve ligation, whereas the effects of morphine administered in the periaqueductal gray region was increased. 39
Spinal nerve injury produces a discrete ipsilateral loss of μ-opioid receptors in laminae I and II of the spinal cord at the level of injury. 40
These observations suggest that supraspinal sites may be involved in the enhanced μ-opioid receptor–mediated pain modulation after nerve injury. Other studies in animal models of neuropathic pain, however, point to a possible peripheral opioid receptor–mediated modulation of pain. 9,41
The mechanisms leading to contralateral increases in pain behavior are uncertain. Bilateral changes may result from crossing projections from primary afferents or intrinsic spinal neurons. It has been postulated that the mechanism linking the two sides of the body is via
spinal interneurons that cross the midline rather than by peripheral mechanism (reviewed by Koltzenburg et al
1999). Nerve injury may also activate descending pain modulating pathways from brain stem nuclei that have opioidergic neurons. Additional studies are needed to determine which of these potential mechanisms play a critical role in the development of tonic bilateral inhibition of pain after nerve injury.
The lack of a difference in hyperalgesia to thermal stimuli after nerve injury between the wild-type and the μ-opioid receptor knockout mice was an unexpected but interesting observation. These observations suggest that the mechanical allodynia and thermal hyperalgesia that develop after nerve injury have distinct mechanisms. Moreover, our findings indicate a differential effect of spinal nerve injury–induced endogenous μ-opioid receptor–mediated inhibition on mechanical allodynia versus
thermal hyperalgesia. It has been postulated that central mechanisms are involved in mechanical allodynia, whereas peripheral mechanisms contribute to heat hyperalgesia. 43
Studies using resiniferatoxin to selectively abolish vanilloid receptor 1–sensitive C fibers indicate that whereas heat hyperalgesia is signaled by C fibers, the mechanical hyperalgesia may be independent of C fiber activity. 44
Recent observations that the N
-methyl-d-aspartate receptor antagonist MK-801 dose-dependently ameliorated Freund’s adjuvant–induced mechanical allodynia but did not significantly affect thermal hyperalgesia support the hypothesis that the mechanisms of mechanical and thermal hyperalgesia differ. 45
Similar neurochemical distinctions in the mechanisms of hyperalgesia to mechanical and thermal stimuli after nerve injury have been postulated. 46
For example, the absence of neurokinin-1 receptors results in attenuation of mechanical but not thermal hyperalgesia after spinal nerve injury. 47
The intrathecal administration of the N
-methyl-d-aspartate antagonist AP-5 reversed mechanical allodynia but was ineffective on thermal hyperalgesia in a rat model of spinal cord injury pain. 48
Nerve injury leads to a reduction in the potency and efficacy of intrathecal morphine in attenuating the response to noxious heat stimuli. 49
In previous studies, neuropathic pain has been reported to be resistant to opioids. In various animal models of neuropathic pain, both increased and decreased effects of opioids have been shown. 7–11
Studies suggest that systemic and supraspinal administration of opioids are able to suppress enhanced responsiveness to mechanical stimuli after nerve injury, whereas spinal opioids are not. 50,51
However, a recent electrophysiologic study in spinal nerve–injured rats suggested that spinal morphine has enhanced potency on C-fiber and noxious mechanical and thermal stimuli–evoked spinal neuronal responses 7–10 days after nerve injury. However, this enhanced potency of morphine tended to decrease at 14–17 days after spinal nerve injury. 52
Results from the current study suggest that systemically administered morphine is able to attenuate neuropathic pain. These experimental observations are consistent with recent clinical reports from our group as well as from other investigators that opioids attenuate but do not abolish peripheral and central neuropathic pain. 4–6
Also, our results suggest that the antihyperalgesic effects of morphine on neuropathic pain are primarily mediated via
μ-opioid receptors. This finding is consistent with previous studies using various acute nociceptive tests that show that the analgesic actions of morphine are mediated predominantly by μ-opioid receptors. 13–15
In the current study, the κ-opioid agonist U50488H was effective in attenuating mechanical hyperalgesia dose dependently in μ-opioid receptor knockout and wild-type mice. This finding is in line with previous observations that the κ-opioid agonist GR89696 was effective in decreasing the enhanced responses to mechanical, heat, and cooling stimuli in a chronic constriction injury model of neuropathic pain. 53
Also, in a rat model of surgical pain, κ-opioid agonists blocked the mechanical and heat hyperalgesia. 54
Results from the current study also suggest that the κ-opioid receptor–mediated effects on neuropathic pain are not modulated by the μ-opioid receptor. This observation is consistent with previous studies showing that κ-opioid receptor–mediated analgesia is not affected in the μ-opioid receptor knockout mice in various acute pain tests. 15,16
In conclusion, we have demonstrated that μ-opioid receptor contributes to the severity of mechanical but not thermal hypersensitivity in a spinal nerve injury model of neuropathic pain. The current study suggests that endogenous opiates acting via μ-opioid receptors exert a tonic inhibitory role in suppressing mechanical allodynia induced by nerve injury. We have also demonstrated that systemically administered morphine acting via μ-opioid receptors is effective in reversing mechanical allodynia in neuropathic pain, and we support the use of opioids for clinical neuropathic pain states. In addition, the κ-opioid agonist, U50488H, is also effective in attenuating mechanical allodynia, and this class of drugs may be worthy of clinical investigation.
The authors thank Antti Pertovaara, M.D., Ph.D. (Professor, Department of Physiology, University of Turku, Turku, Finland), Matthias Ringkamp, M.D. (Assistant Professor, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland), and Yun Guan, Ph.D. (Postdoctoral Fellow, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine) for their thoughtful review and comments on the manuscript.
1. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 11–23
2. Stein C: The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332: 1685–90
3. Ossipov MH, Kovelowski CJ, Porreca F: The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective delta-opioid antagonist. Neurosci Lett 1995; 184: 173–6
4. Watson CPN, Babul N: Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837–41
5. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB: Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2002; 59: 1015–21
6. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348: 1223–32
7. Attal N, Chen YL, Kayser V, Guilbaud G: Behavioural evidence that systemic morphine may modulate a phasic pain-related behaviour in a rat model of peripheral mononeuropathy. Pain 1991; 47: 65–70
8. Yamamoto T, Yaksh TL: Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 1992; 135: 67–70
9. Kayser V, Lee SH, Guilbaud G: Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy. Neuroscience 1995; 64: 537–45
10. Mao J, Price DD, Mayer DJ: Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 61: 353–64
11. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F: The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett 1995; 199: 87–90
12. Kieffer BL: Opioids: First lessons from knockout mice. Trends Pharmacol Sci 1999; 20: 19–26
13. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819–23
14. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR: Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A 1997; 94: 1544–9
15. Fuchs PN, Roza C, Sora I, Uhl G, Raja SN: Characterization of mechanical withdrawal responses and effects of mu-, delta- and kappa-opioid agonists in normal and mu-opioid receptor knockout mice. Brain Res 1999; 821: 480–6
16. Matthes HWD, Smadja C, Valverde O, Vonesch J-L, Foutz AS, Boudinot E, Denavit-Saubié M, Severini C, Negri L, Roques BP, Maldonado R, Kieffer BL: Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci 1998; 18: 7285–95
17. Sora I, Funada M, Uhl GR: The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia. Eur J Pharmacol 1997; 324: R1–2
18. Wiesenfeld-Hallin Z, Aldskogius H, Grant G, Hao JX, Hokfelt T, Xu XJ: Central inhibitory dysfunctions: Mechanisms and clinical implications. Behav Brain Sci 1997; 20: 420–5
19. Woolf CJ, Salter MW: Neuronal plasticity: Increasing the gain in pain. Science 2000; 288: 1765–9
20. Przewlocka B, Lason W, Przewlocki R: Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats: A release and in situ hybridization study. Neuroscience 1992; 46: 209–16
21. Maekawa K, Minami M, Masuda T, Satoh M: Expression of μ- and kappa-, but not δ-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain 1996; 64: 365–71
22. Calza L, Pozza M, Arletti R, Manzini E, Hokfelt T: Long-lasting regulation of galanin, opioid, and other peptides in dorsal root ganglia and spinal cord during experimental polyarthritis. Exp Neurol 2000; 164: 333–43
23. Hurley RW, Hammond DL: The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci 2000; 20: 1249–59
24. Hurley RW, Hammond DL: Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury. J Neurosci 2001; 21: 2536–45
25. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355–63
26. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM: Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994; 59: 369–76
27. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988; 32: 77–88
28. Kitchen I: Opioid gene knockouts: New answers to old questions? Opioid Sensitivity of Chronic Noncancer Pain, Progress in Pain Research and Management. Edited by Kalso E, McQuay H, Wiesenfeld-Hallin Z. Seattle, IASP Press, 1999, pp 281–303
29. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M: Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception. Pain 1999; 80: 67–82
30. Kitchen I, Slowe SJ, Matthes HW, Kieffer B: Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res 1997; 778: 73–88
31. el Sobky A, Dostrovsky JO, Wall PD: Lack of effect of naloxone on pain perception in humans. Nature 1976; 263: 783–4
32. Grevert P, Goldstein A: Endorphins: Naloxone fails to alter experimental pain or mood in humans. Science 1978; 199: 1093–5
33. Hao JX, Yu W, Xu XJ: Evidence that spinal endogenous opioidergic systems control the expression of chronic pain-related behaviors in spinally injured rats. Exp Brain Res 1998; 118: 259–68
34. Levine JD, Gordon NC, Jones RT, Fields HL: The narcotic antagonist naloxone enhances clinical pain. Nature 1978; 272: 826–7
35. Attal N, Kayser V, Guilbaud G: The bidirectional dose-dependent effect of systemic naloxone is also related to the intensity and duration of pain-related disorders: A study in a rat model of peripheral mononeuropathy. Brain Res 1990; 525: 170–4
36. Stevens CW, Kajander KC, Bennett GJ, Seybold VS: Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy. Pain 1991; 46: 315–26
37. Seltzer Z, Dubner R, Shir Y: A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205–18
38. Hurley RW, Hammond DL: The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci 2000; 20: 1249–59
39. Pertovaara A, Wei H: A dissociative change in the efficacy of supraspinal versus spinal morphine in the neuropathic rat. Pain 2003; 101: 237–50
40. Porreca F, Tang QB, Bian D, Riedl M, Elde R, Lai J: Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res 1998; 795: 197–203
41. Pertovaara A, Wei H: Peripheral effects of morphine in neuropathic rats: Role of sympathetic postganglionic nerve fibers. Eur J Pharmacol 2001; 429: 139–45
42. Koltzenburg M, Wall PD, McMahon SB: Does the right side know what the left is doing? Trends Neurosci 1999; 22: 122–7
43. Treede R-D, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992; 38: 397–421
44. Ossipov MH, Bian D, Malan TP Jr, Lai J, Porreca F: Lack of involvement of capsaicin-sensitive primary afferents in nerve-ligation injury induced tactile allodynia in rats. Pain 1999; 79: 127–33
45. Hama A, Woon LJ, Sagen J: Differential efficacy of intrathecal NMDA receptor antagonists on inflammatory mechanical and thermal hyperalgesia in rats. Eur J Pharmacol 2003; 459: 49–58
46. Ossipov MH, Lai J, Malan TP Jr, Porreca F: Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci 2000; 909: 12–24
47. Mansikka H, Sheth RN, DeVries C, Lee H, Winchurch R, Raja SN: Nerve injury-induced mechanical but not thermal hyperalgesia is attenuated in neurokinin-1 receptor knockout mice. Exp Neurol 2000; 162: 343–9
48. Bennett AD, Everhart AW, Hulsebosch CE: Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res 2000; 859: 72–82
49. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995; 199: 83–6
50. Bian D, Nichols ML, Ossipov MH, Lai J, Porreca F: Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport 1995; 6: 1981–4
51. Lee Y-W, Chaplan SR, Yaksh TL: Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci Lett 1995; 186: 111–4
52. Suzuki R, Chapman V, Dickenson AH: The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain 1999; 80: 215–28
53. Eliav E, Herzberg U, Caudle RM: The kappa opioid agonist GR89,696 blocks hyperalgesia and allodynia in rat models of peripheral neuritis and neuropathy. Pain 1999; 79: 255–64
54. Field MJ, Carnell AJ, Gonzalez MI, McCleary S, Oles RJ, Smith R, Hughes J, Singh L: Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain 1999; 80: 383–9
This article has been cited 22 time(s).
Evidence-Based Complementary and Alternative MedicineOn the G-Protein-Coupled Receptor Heteromers and Their Allosteric Receptor-Receptor Interactions in the Central Nervous System: Focus on Their Role in Pain ModulationEvidence-Based Complementary and Alternative Medicine
Molecular PainTRPV1, but not TRPA1, in primary sensory neurons contributes to cutaneous incision-mediated hypersensitivityMolecular Pain
Canadian Journal of Anesthesia-Journal Canadien D AnesthesieEvaluation of a novel mouse model of intracisternal strychnine-induced trigeminal allodyniaCanadian Journal of Anesthesia-Journal Canadien D Anesthesie
NeurosciencePharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in miceNeuroscience
Neuroscience LettersPretreatment with antiserum against dynorphin, substance P, or cholecystokinin enhances the morphine-produced anti-allodynia in the sciatic nerve ligated miceNeuroscience Letters
Journal of NeuroscienceWindup in dorsal horn neurons is modulated by endogenous spinal mu-opioid mechanismsJournal of Neuroscience
PainEndogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammationPain
Current Pain and Headache ReportsSpinal inhibitory neurotransmission in neuropathic painCurrent Pain and Headache Reports
Emerging Strategies for the Treatment of Neuropathic Pain
Peripheral receptors in neuropathic pain
Emerging Strategies for the Treatment of Neuropathic Pain, ():
PainLoss of spinal mu-opioid receptor is associated with mechanical allodynia in a rat model of peripheral neuropathyPain
Neuroscience LettersA partial L5 spinal nerve ligation induces a limited prolongation of mechanical allodynia in rats: An efficient model for studying mechanisms of neuropathic painNeuroscience Letters
Journal of NeuroscienceBAMBI (Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor) Reveals the Involvement of the Transforming Growth Factor-beta Family in Pain ModulationJournal of Neuroscience
Journal of Neuroscience ResearchCharacterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changesJournal of Neuroscience Research
NeuroscienceULTRA-LOW DOSE NALOXONE RESTORES THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN PERTUSSIS TOXIN-TREATED RATS BY REVERSING THE COUPLING OF mu-OPIOID RECEPTORS FROM Gs-PROTEIN TO COUPLING TO Gi-PROTEINNeuroscience
Neurochemical ResearchMu-opioid receptor in the nucleus submedius: Involvement in opioid-induced inhibition of mirror-image allodynia in a rat model of neuropathic painNeurochemical Research
NeuropharmacologyDepression of C fibre-evoked spinal field potentials by the spinal delta opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: Involvement of the mu-subtypeNeuropharmacology
Journal of NeurochemistryThe effects of local perfusion of DAMGO on extracellular GABA and glutamate concentrations in the rostral ventromedial medullaJournal of Neurochemistry
PainEffect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent painPain
Emerging Strategies for the Treatment of Neuropathic Pain
Opioids and neuropathic pain
Emerging Strategies for the Treatment of Neuropathic Pain, ():
PeptidesEndogenous opiates and behavior: 2004Peptides
Journal of NeuroscienceUpregulation of the voltage-gated sodium channel beta 2 subunit in neuropathic pain models: Characterization of expression in injured and non-injured primary sensory neuronsJournal of Neuroscience
European Journal of NeuroscienceInflammatory pain is enhanced in delta opioid receptor-knockout miceEuropean Journal of Neuroscience
© 2004 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.